Fuse Oncology Closes Funding Round with Support from Leading Health Systems in the Southern U.S.
ncarol.com/10223769

GREENSBORO, N.C., June 1, 2023 ~ Fuse Oncology, an oncology software solutions company, has announced the successful closing of its oversubscribed Series A. Cone Health Ventures and Northeast Georgia Health Ventures (NGHV) were among the largest contributors to the round. The investments will be used to accelerate the expansion of Fuse Oncology's first commercial product, S!GNAL, and develop additional solutions in the radiation oncology market.

James Bauler, CEO of Fuse Oncology, Inc., expressed his gratitude for the investors' enthusiasm and interest in their product. "We are grateful for the interest and enthusiasm of investors who understand the significant impact of our product and our potential to thrive in the market," said Bauler.

Fuse Oncology was spun out of Cone Health and signed its first revenues in quarter one of 2022. Their technology is designed to address key challenges that face radiation oncology departments by automatically identifying and tracking missing documentation, incomplete tasks and orders, as well as wrong charges entered.

More on ncarol.com

• New from Regal House Publishing, The Meaning of Fear, a psychological crime drama
• New plusOne Research Finds the Orgasm Gap Is a 30-Point Chasm — and Confirms It Isn't Biology
• CCHR Report Links 145 Violent Incidents to Psychiatric Drug Exposure, Urges National Oversight and Action
• Food Journal Magazine Unveils Its Latest 'Best of Los Angeles' Culinary Discoveries
• Boston Industrial Solutions Launches Natron® 717S Series: A New Flexible UV LED Ink for Ricoh GH2220 Printheads

John Miller, chief investment officer at Cone Health, expressed his confidence in leading this funding round to support Fuse Oncology's growth. "Fuse has made phenomenal progress in establishing a foothold in the radiation oncology market," said Miller. "We are confident in leading this funding round to support their growth and help expand their reach."

S!GNAL technology from Fuse Oncology catches issues before they materialize to drastically improve revenue cycle and clinical staff workflows. By minimizing mistakes in coding and documentation processes, it has uncovered substantial lost revenues for providers. Additional solutions from Fuse address challenges in patient engagement cycles to reduce average time to treatment.

Stuart Burri, MD, chairman of radiation oncology at Levine Cancer Institute, president of Southeast Radiation Oncology Group (SERO), and an early investor continues to support Fuse Oncology's advancement. "Fuse's rapid expansion in local radiation oncology centers has changed the way we're thinking about business," said Dr Burri. "It's exciting to reimagine a seamless workflow and data experience between radiation oncology departments and health systems."

Fuse Oncology's Series A closing marks a major milestone for them as they continue their mission to make rad onc departments more efficient while supporting substantial growth in volumes and revenues throughout 2023.

---

Show All News | Disclaimer | Report Violation